Collegium Board Authorizes $35M Accelerated Share Repurchase Program
Portfolio Pulse from Benzinga Newsdesk
The board of Collegium Pharmaceutical has authorized a $35 million accelerated share repurchase (ASR) program. This move is aimed at returning value to shareholders by reducing the number of shares outstanding, potentially increasing the earnings per share (EPS) and the stock price in the short term.
May 09, 2024 | 9:13 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Collegium Pharmaceutical's $35M ASR program is expected to positively impact its stock price by reducing shares outstanding and potentially increasing EPS.
Accelerated share repurchase programs are generally viewed positively by the market as they indicate the company's confidence in its financial health and future prospects. By reducing the number of shares outstanding, EPS may increase, which can lead to a higher stock price. However, the actual impact will depend on market conditions and investor perceptions.
CONFIDENCE 90
IMPORTANCE 85
RELEVANCE 100